|
| August 27, 2019 |
Bevacizumab for First-Line Treatment of Hormone Receptor-Positive Metastatic Breast Cancer?
Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that binds to vascular endothelial growth factor (VEGF) and prevents VEGF from attaching to its receptor on endothelial cells, thereby producing antiangiogenic effects that result in a reduction of microvascular growth and inhibition of metastatic-disease progression. What role, if any, does it have in breast cancer? Read more. |
|
|
CAM Interactions in Breast and Other Gynecological Cancers
The use of complementary and alternative medicine (CAM) is widespread among oncology patients, with up to one-half of patients using one form or another. Various reasons for the widespread use of CAM among this population include attempts to decrease disease or treatment-related symptoms, improve quality of life, gain additional benefit over conventional treatments, and maintain greater control of the treatment process. Read more. |
|
Multidisciplinary Approach to Toxicities Associated With
Targeted Therapies
The use of targeted therapies for locally advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer has greatly enhanced progression-free survival, objective response, and clinical benefit compared with endocrine monotherapy. However, these new therapies are associated with more complex and potentially severe adverse events compared with hormonal therapy. Read more. |
|
|
Connect With U.S. Pharmacist
    |
|
|
|
|
